
BMS to Invest $400 Million in Expansion of Dublin Site
Bristol Myers Squibb (BMS) wants to invest $400 million for the construction and design of a sterile drug product (SDP) facility at its Cruiserath campus in Dublin, Ireland, significantly expanding manufacturing and laboratory capacity at the site.